Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. Other stock markets 15/07/2026			5-day change	1st Jan Change
969.77 ^PKR	+0.16%		-4.02%	-5.16%

05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI
04-30	Highnoon Laboratories Limited Approves Final Cash Dividend for the Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	52,225	-	-
Change	-	11.36%	-3.6%	-	-
Enterprise Value (EV)	48,650	54,175	52,225	52,225	52,225
Change	-	11.36%	-3.6%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.72x	1.53x	1.36x
EV / Revenue	-	0x	1.72x	1.53x	1.36x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.64%	5.36%	6.19%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	969.77	969.77	969.77
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/03/25	07/04/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.64%	185M
ELI LILLY AND COMPANY	34.38x	12.29x	25.6x	0.58%	1,031B
JOHNSON & JOHNSON	26.33x	6.06x	16.38x	2.17%	595B
ABBVIE INC.	30.03x	7.25x	14.87x	2.81%	431B
ROCHE HOLDING AG	17.64x	4.37x	10.78x	3.03%	326B
NOVARTIS AG	21.13x	5.43x	13.15x	2.91%	277B
ASTRAZENECA PLC	21.17x	4.46x	12.34x	1.97%	263B
NOVO NORDISK A/S	14.47x	5.42x	11.17x	3.43%	224B
AMGEN INC.	23.5x	6.23x	11.02x	2.81%	193B
GILEAD SCIENCES, INC.	-47.44x	5.68x	31.37x	2.46%	164B
Average	15.69x	6.36x	16.30x	2.68%	350.45B
Weighted average by Cap.	23.19x	7.66x	17.90x	2.04%